Lipocine’s product, LPCN-1144, has promising results in decreasing the risk of NASH in non-alcoholic fatty liver disease

Lipocine (LPCN), a specialty pharmaceutical company, announced that an approximately eight-week top-line study using LPCN 1144 in subjects with non-alcoholic fatty liver disease (NAFLD) who might have the potential to develop NASH. 
Treatment results showed an absolute mean reduction from baseline of 7.6% liver fat and demonstrated a 38% relative mean liver fat reduction from baseline. Moreover, there was an 86% responder rate in which subjects experienced at least a 4.1% absolute reduction in liver fat from baseline and a 71% responder rate who experienced at least a 29 . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.